Cardiovascular

“RADIANCE-1″ Study: Cholesteryl Ester Transfer Protein Inhibitor Fails to Benefit Patients with Familial Hypercholesterolemia

John Kastelein

JOHN KASTELEIN, Academic Medical Center, Amsterdam

REFERENCE: Abstract 407-7, American College of Cardiolgy New Orleans
A drug which raises HDL and reduces circulating levels of LDL has nevertheless failed to reduce atherosclerotic progression in patients with familial hypercholesterolemia. This disappointing outcome of a study using the cholesteryl ester transfer protein inhibitor (CETP), torcetrapib, was announced at the American College of Cardiology meeting in New Orleans. John Kastelein discussed the findings, and their implications for therapies targeting HDL, with Peter Goodwin.

Similar Interviews

  • Torcetrapib in Patients at High Risk for Coronary Events: ILLUMINATE Trial Latest Results
  • Philip Barter Gordon Tomaselli REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions,

  • COURAGE Trial: Optimal Medical Therapy Alone is Sufficient for Patients with Stable Angina: Adding PCI Does Not Help - ILLUSTRATE Study Shows Torcetrapib Raises HDL But Fails to Lower Coronary Risk
  • STEVEN NISSEN, Cleveland Clinic, OH REFERENCE: N Engl J Med 2007 356 Reporting from: American College of Cardiolgy New Orleans Two big studies

  • Audio Journal of Medicine: Single Embryo Transfer: Just as High Live Birth Rates as Double Transfer, But Without Risks
  • &ot

    Post a comment

    Subscribe to Audio Medica Podcast